Arcutis Biotherapeutics

ARQT

31.2153.06% ( -0.985 )

Trading: Oct 23, 12:36:50 (EDT)

Q2 FY2026 EarningsQ2 FY26 beat consensus significantly across all key metrics: revenue of $129.9M vs. $118.9M expected (+9.26%), and GAAP EPS of $0.11 vs. $0.03 expected. ZORYVE net product sales grew 59% YoY, driven by strong demand and improved gross-to-net pricing. Management raised full-year FY26 sales guidance to $525M–$540M, well above previous ranges, signaling sustained commercial momentum in the dermatology market.

Financial report interval: 2026.03.30 - 2026.06.30

Overview: Arcutis Biotherapeutics(ARQT) the Revenue is 129.86 M (+59.33%), Beat estimate;the EBIT is 16.43 M (+212.4%), Beat estimate;the EPS is 0.11 (+184.6%), Beat estimate.

Actual

YoY

Estimate

YoY

Vs estimate

YoY

RevenueExceed expectations

0.13B59.33%

0.12B45.82%

+0.01B13.51%

EBITExceed expectations

0.02B212.44%

0.00B123.92%

+0.01B88.52%

EPSExceed expectations

0.11184.62%

0.0283121.79%

+0.081762.83%

Upcoming earnings report - Q3 FY2026

Available dateNov 4, 2026

Estimate Revenue$142.59 M

Estimate EBIT$21.9 M

Estimate EPS$0.16

Revenue

ActualEstimateUnit: USD

Quarterly

EBIT

ActualEstimateUnit: USD

Quarterly

Net income

ActualEstimateUnit: USD

Quarterly

EPS

ActualEstimateUnit: USD

Quarterly